A new composition has been developed that incorporates S1P into a conventional demineralized bone matrix material. Once the device is implanted into the spine, the S1P will elute out of the device, thereby setting up a concentration gradient in the vicinity of the device. This gradient will cause stem cells to preferentially migrate to the device.

A new composition has been developed that incorporates S1P into a conventional demineralized bone matrix material. Once the device is implanted into the spine, the S1P will elute out of the device, thereby setting up a concentration gradient in the vicinity of the device. This gradient will cause stem cells to preferentially migrate to the device.

The Stem Cell Delivery Device comprises an Introducer, a Catheter, and Pressure Metered Injector Syringe. The device and method aim to deliver stem cells abundantly enough at the damaged site to allow recovery and restore function. The Method uses activated Stem Cells. It entails injecting via the Syringe Injector the epidural space with raw adipose tissue extract to circle the spinal cord about a level above and below the injured cord site till blockade of the subarachnoid space of the injured spinal cord site is achieved and radiographically verified. Then washed activated stem cells are injected via the Syringe into the blocked subarachnoid space to bridge between the upper and lower normal spinal tract, allowing the stem cells to grow new spinal tracts to connect and bridge over the damaged site. IV infusion of bone marrow stem cells is added to maximize the chance of recovery.

The Stem Cell Delivery Device comprises an Introducer, a Catheter, and Pressure Metered Injector Syringe. The device and method aim to deliver stem cells abundantly enough at the damaged site to allow recovery and restore function. The Method uses activated Stem Cells. It entails injecting via the Syringe Injector the epidural space with raw adipose tissue extract to circle the spinal cord about a level above and below the injured cord site till blockade of the subarachnoid space of the injured spinal cord site is achieved and radiographically verified. Then washed activated stem cells are injected via the Syringe into the blocked subarachnoid space to bridge between the upper and lower normal spinal tract, allowing the stem cells to grow new spinal tracts to connect and bridge over the damaged site. IV infusion of bone marrow stem cells is added to maximize the chance of recovery.

Methods and materials for reducing organ transplant rejection or minimizing ischemia or ischemia/reperfusion injury in a subject are described. The methods include administering a fat emulsion before or after the organ transplant or before, at the onset of, or after the ischemic event.

Methods and materials for reducing organ transplant rejection or minimizing ischemia or ischemia/reperfusion injury in a subject are described. The methods include administering a fat emulsion before or after the organ transplant or before, at the onset of, or after the ischemic event.

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

Described herein are stem cells and stem cell compositions that can be used to treat soft tissue injuries, including tendon and ligament injuries. Also described herein are cellular scaffolds that can contain a stem cell or stem cell compositions described herein. Also described herein are soft tissue bioreactor devices. Also described herein are methods of using the stem cells, stem cell compositions, and soft tissue bioreactors and methods of treating tendon and ligament injuries.

Preparation of a product comprising stromal vascular fraction cells includes washing human biological material comprising adipose in a container apparatus having an internal filter, which divides an internal containment volume of the container apparatus into a tissue retention volume on one side of the filter and a filtrate volume on an opposite side of the filter, and a mixing device with at least one rotatable mixing member disposed in the tissue retention volume. The washing includes operation of the mixing device to rotate the mixing member through the human biological material within the tissue retention volume, and the washing is followed by digesting washed material within the internal containment volume with added enzyme, centrifuging of the container apparatus to prepare a centrifuged pellet in the filtrate volume, selectively removing material of the pellet and preparing a product with a mixture of stromal vascular fraction cells of removed pellet material and an aqueous suspension liquid.